Corinna Lau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8019257/publications.pdf

Version: 2024-02-01

		759233	888059
18	867	12	17
papers	citations	h-index	g-index
19	19	19	1481
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Thrombin Differentially Modulates the Acute Inflammatory Response to <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> in Human Whole Blood. Journal of Immunology, 2022, 208, 2771-2778.	0.8	1
2	Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood. Journal of Immunology, 2021, 207, 2828-2840.	0.8	5
3	NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies. MAbs, 2020, 12, 1686319.	5.2	2
4	Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood. Journal of Immunology, 2019, 203, 1571-1578.	0.8	27
5	Combined Inhibition of C5 and CD14 Attenuates Systemic Inflammation in a Piglet Model of Meconium Aspiration Syndrome. Neonatology, 2018, 113, 322-330.	2.0	7
6	Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsis. Journal of Intensive Care, 2017, 5, 21.	2.9	17
7	Combined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4–MD2 Complex. Journal of Infectious Diseases, 2016, 214, 140-150.	4.0	13
8	Human Endothelial Cell Activation by <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> Is Mediated by TNF and IL- $1\hat{1}^2$ Secondarily to Activation of C5 and CD14 in Whole Blood. Journal of Immunology, 2016, 196, 2293-2299.	0.8	13
9	Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis. Critical Care, 2015, 19, 415.	5.8	32
10	Gene expression profiling of Gram-negative bacteria-induced inflammation in human whole blood: The role of complement and CD14-mediated innate immune response. Genomics Data, 2015, 5, 176-183.	1.3	6
11	The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clinical and Experimental Immunology, 2015, 181, 457-467.	2.6	8
12	Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology, 2015, 220, 452-459.	1.9	90
13	CD14 and Complement Crosstalk and Largely Mediate the Transcriptional Response to Escherichia coli in Human Whole Blood as Revealed by DNA Microarray. PLoS ONE, 2015, 10, e0117261.	2.5	16
14	Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation. Journal of Immunology, 2013, 191, 4769-4777.	0.8	34
15	Development of Î ² -Amino Alcohol Derivatives That Inhibit Toll-like Receptor 4 Mediated Inflammatory Response as Potential Antiseptics. Journal of Medicinal Chemistry, 2011, 54, 4659-4669.	6.4	30
16	Isoform-specific Targeting and Interaction Domains in Human Nicotinamide Mononucleotide Adenylyltransferases. Journal of Biological Chemistry, 2010, 285, 18868-18876.	3.4	54
17	Regulation of poly(ADP-ribose) polymerase 1 activity by the phosphorylation state of the nuclear NAD biosynthetic enzyme NMN adenylyl transferase 1. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3765-3770.	7.1	97
18	Subcellular Compartmentation and Differential Catalytic Properties of the Three Human Nicotinamide Mononucleotide Adenylyltransferase Isoforms. Journal of Biological Chemistry, 2005, 280, 36334-36341.	3.4	414